Literature DB >> 1898901

Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.

S J Cryz1, E Fürer, J U Que.   

Abstract

Alginate from Pseudomonas aeruginosa 3064 was depolymerized by controlled heating in dilute acid. The resulting depolymerized alginate (Mr less than 60,000) was covalently coupled to toxin A with adipic acid dihydrazide as a spacer molecule and carbodiimide as a linker. The resulting conjugate was composed of toxin A and depolymerized alginate at a ratio of 4:1 and possessed an Mr of 260,000. The conjugate was nontoxic and nonpyrogenic. While native alginate (Mr greater than 640,000) given in a range of doses was poorly immunogenic in mice and rabbits, the conjugate induced high levels of antibody which bound to native alginate. Rabbits, but not mice, also produced an antitoxin immunoglobulin antibody response. Alginate derived from three other strains of P. aeruginosa competed with the homologous 3064 alginate for binding to anticonjugate antibody. This indicates that the conjugate elicits an antibody response able to recognize heterologous alginates. The serum from rabbits immunized with the conjugate was effective at promoting the uptake and killing of mucoid strains of P. aeruginosa by human polymorphonuclear leukocytes. In contrast, immunization with native alginate did not engender an opsonic antibody response. Rabbit anticonjugate antibody also neutralized the cytotoxic potential of toxin A.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898901      PMCID: PMC257703          DOI: 10.1128/iai.59.1.45-50.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  28 in total

1.  Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis.

Authors:  G B Winnie; R G Cowan; N A Wade
Journal:  J Pediatr       Date:  1989-02       Impact factor: 4.406

2.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis.

Authors:  R B Moss; Y P Hsu; N J Lewiston; J G Curd; H Milgrom; S Hart; B Dyer; J W Larrick
Journal:  Am Rev Respir Dis       Date:  1986-04

4.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells.

Authors:  R Ramphal; G B Pier
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

7.  Alginate inhibition of the uptake of Pseudomonas aeruginosa by macrophages.

Authors:  J A Simpson; S E Smith; R T Dean
Journal:  J Gen Microbiol       Date:  1988-01

8.  Immune complexes and Pseudomonas aeruginosa antibodies in cystic fibrosis.

Authors:  H P Van Bever; P L Gigase; L S De Clerck; C H Bridts; H Franckx; W J Stevens
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

9.  Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; G H Shand
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

10.  Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.

Authors:  G B Pier; J M Saunders; P Ames; M S Edwards; H Auerbach; J Goldfarb; D P Speert; S Hurwitch
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

View more
  11 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

Authors:  Victoria L Campodónico; Nicolas J Llosa; Leticia V Bentancor; Tomas Maira-Litran; Gerald B Pier
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

3.  A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis.

Authors:  Laura Silo-Suh; Sang-Jin Suh; Pamela A Sokol; Dennis E Ohman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

4.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Authors:  Christian Theilacker; Fadie T Coleman; Simone Mueschenborn; Nicolas Llosa; Martha Grout; Gerald B Pier
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

6.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

7.  Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Authors:  K Hatano; G B Pier
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

8.  Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.

Authors:  Leila Safari Zanjani; Reza Shapouri; Mehrouz Dezfulian; Mehdi Mahdavi; Mehdi Shafiee Ardestani
Journal:  World J Microbiol Biotechnol       Date:  2019-06-11       Impact factor: 4.253

9.  Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid.

Authors:  Faezeh Najafzadeh; Ghazaleh Jaberi; Reza Shapouri; Mehdi Rahnema; Ashraf Karimi-Nik; Anvarsadat Kianmehr
Journal:  Iran J Microbiol       Date:  2014-10

10.  Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine.

Authors:  Saeid Azimi; Leila Safari Zanjani
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.